159 related articles for article (PubMed ID: 16373719)
1. Anti-CD70 antibodies: a potential treatment for EBV+ CD70-expressing lymphomas.
Israel BF; Gulley M; Elmore S; Ferrini S; Feng WH; Kenney SC
Mol Cancer Ther; 2005 Dec; 4(12):2037-44. PubMed ID: 16373719
[TBL] [Abstract][Full Text] [Related]
2. Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.
Kenney S
Trans Am Clin Climatol Assoc; 2006; 117():55-73; discussion 73-4. PubMed ID: 18528464
[TBL] [Abstract][Full Text] [Related]
3. Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes.
Murphy WJ; Funakoshi S; Beckwith M; Rushing SE; Conley DK; Armitage RJ; Fanslow WC; Rager HC; Taub DD; Ruscetti FW
Blood; 1995 Sep; 86(5):1946-53. PubMed ID: 7544649
[TBL] [Abstract][Full Text] [Related]
4. Indole-3-carbinol induces cMYC and IAP-family downmodulation and promotes apoptosis of Epstein-Barr virus (EBV)-positive but not of EBV-negative Burkitt's lymphoma cell lines.
Perez-Chacon G; de Los Rios C; Zapata JM
Pharmacol Res; 2014 Nov; 89():46-56. PubMed ID: 25180456
[TBL] [Abstract][Full Text] [Related]
5. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
Lapalombella R; Zhao X; Triantafillou G; Yu B; Jin Y; Lozanski G; Cheney C; Heerema N; Jarjoura D; Lehman A; Lee LJ; Marcucci G; Lee RJ; Caligiuri MA; Muthusamy N; Byrd JC
Clin Cancer Res; 2008 Jan; 14(2):569-78. PubMed ID: 18223233
[TBL] [Abstract][Full Text] [Related]
6. Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.
Cardarelli PM; Quinn M; Buckman D; Fang Y; Colcher D; King DJ; Bebbington C; Yarranton G
Cancer Immunol Immunother; 2002 Mar; 51(1):15-24. PubMed ID: 11845256
[TBL] [Abstract][Full Text] [Related]
7. Induction of CD44 expression by the Epstein-Barr virus latent membrane protein LMP1 is associated with lymphoma dissemination.
Walter J; Schirrmacher V; Mosier D
Int J Cancer; 1995 May; 61(3):363-9. PubMed ID: 7537255
[TBL] [Abstract][Full Text] [Related]
8. B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas.
Yokochi T; Holly RD; Clark EA
J Immunol; 1982 Feb; 128(2):823-7. PubMed ID: 6274961
[TBL] [Abstract][Full Text] [Related]
9. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo.
Aulwurm S; Wischhusen J; Friese M; Borst J; Weller M
Int J Cancer; 2006 Apr; 118(7):1728-35. PubMed ID: 16217761
[TBL] [Abstract][Full Text] [Related]
10. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
11. Signaling through CD70 regulates B cell activation and IgG production.
Arens R; Nolte MA; Tesselaar K; Heemskerk B; Reedquist KA; van Lier RA; van Oers MH
J Immunol; 2004 Sep; 173(6):3901-8. PubMed ID: 15356138
[TBL] [Abstract][Full Text] [Related]
12. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody.
Israel BF; Pickles RJ; Segal DM; Gerard RD; Kenney SC
J Virol; 2001 Jun; 75(11):5215-21. PubMed ID: 11333903
[TBL] [Abstract][Full Text] [Related]
14. Burkitt's lymphoma - a human tumor model system for immunological studies.
Gunvén P
Biochim Biophys Acta; 1975 Dec; 417(3-4):187-210. PubMed ID: 175835
[TBL] [Abstract][Full Text] [Related]
15. Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.
McEarchern JA; Oflazoglu E; Francisco L; McDonagh CF; Gordon KA; Stone I; Klussman K; Turcott E; van Rooijen N; Carter P; Grewal IS; Wahl AF; Law CL
Blood; 2007 Feb; 109(3):1185-92. PubMed ID: 17038522
[TBL] [Abstract][Full Text] [Related]
16. A study of the association of Epstein-Barr virus with Burkitt's lymphoma occurring in a Chinese population.
Chan JK; Tsang WY; Ng CS; Wong CS; Lo ES
Histopathology; 1995 Mar; 26(3):239-45. PubMed ID: 7797201
[TBL] [Abstract][Full Text] [Related]
17. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
Ring NG; Herndler-Brandstetter D; Weiskopf K; Shan L; Volkmer JP; George BM; Lietzenmayer M; McKenna KM; Naik TJ; McCarty A; Zheng Y; Ring AM; Flavell RA; Weissman IL
Proc Natl Acad Sci U S A; 2017 Dec; 114(49):E10578-E10585. PubMed ID: 29158380
[TBL] [Abstract][Full Text] [Related]
18. Involvement of CD27/CD70 interactions in antigen-specific cytotoxic T-lymphocyte (CTL) activity by perforin-mediated cytotoxicity.
Yamada S; Shinozaki K; Agematsu K
Clin Exp Immunol; 2002 Dec; 130(3):424-30. PubMed ID: 12452832
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
[TBL] [Abstract][Full Text] [Related]
20. IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBV.
Klein SC; Jücker M; Abts H; Tesch H
Hematol Oncol; 1995; 13(3):121-30. PubMed ID: 7622142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
